Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy-Reference-Cited by-同舟云学术

Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy

Published:2017-05-18 Issue:17 Volume:123 Page:3367-3376
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hwang Jessica P.¹^ORCID,Suarez-Almazor Maria E.¹,Cantor Scott B.²,Barbo Andrea³,Lin Heather Y.³^ORCID,Ahmed Sairah⁴,Chavez-MacGregor Mariana²,Donato-Santana Christian¹,Eng Cathy⁵,Ferrajoli Alessandra⁶,Fisch Michael J.⁷,McLaughlin Peter⁸,Simon George R.⁹,Rondon Gabriela⁴,Shpall Elizabeth J.⁴,Lok Anna S.¹⁰

Affiliation:

1. Department of General Internal Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Health Services Research; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

4. Department of Stem Cell Transplantation; The University of Texas MD Anderson Cancer Center; Houston Texas

5. Department of Gastrointestinal Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

6. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

7. Medical Oncology; Aim Specialty Health; Deerfield Illinois

8. Physicians Network, MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center; Houston Texas

9. Department of Thoracic Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

10. Division of Gastroenterology and Hepatology; University of Michigan; Ann Arbor Michigan

Funder

National Institutes of Health

National Cancer Institute

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30729/fullpdf

Reference17 articles.

1. World Health Organization Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection http://apps.who.int/iris/handle/10665/154590 2015

2. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B;Park;Gastroenterology.,2016

3. Management of patients with hepatitis B who require immunosuppressive therapy;Hwang;Nat Rev Gastroenterol Hepatol.,2014

4. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update;Hwang;J Clin Oncol.,2015

5. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology;Baden;J Natl Compr Canc Netw.,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors;Journal of Immunotherapy and Precision Oncology;2024-05-01

3. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies;Clinical Microbiology and Infection;2022-10

4. Chronic Hepatitis B;Clinical Cases in Hepatology;2021-10-26

5. Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study;Frontiers in Medicine;2021-07-15